Highlights

• Cynata has received a notice of acceptance from IP Australia for its patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology
• Cynata has also received a notice of allowance from the Canadian government
• Cynata is expecting both the Australian and Canadian patents by January 2023

Cynata Therapeutics Limited (ASX:CYP) has released an update on its Intellectual Property (IP) portfolio. The clinical-stage biotechnology company focused on cell therapeutics received a notice of acceptance from IP Australia for the patent application entitled ‘Colony Forming Medium and Use Thereof’. The patent covers Cynata’s proprietary Cymerus™ mesenchymal stem cell (MSC) technology.

Additionally, the company has received a notice of allowance from the Canadian Intellectual Property Office (CIPO). The notice of allowance is for the same application and for a further patent application entitled ‘Pluripotent Stem Cell Assay’.

What are mesenchymal stem cells (MSCs)?

Mesenchymal stem cells are adult ‘multipotent’ stem cells found in human tissues. They can produce different types of cells, facilitate regeneration, and affect the immune system.

Cynata wholly owns the patent applications which define major aspects of the company’s unique and proprietary cell therapy production technology, Cymerus™.

The notice of acceptance is sent to an applicant when the Australian government’s patent agency (IP Australia) intends to issue a patent. Similarly, an applicant receives a CIPO notice of allowance when the CIPO intends to issue a patent.

Cynata looks forward to developing its patent estate

Cynata expects to receive the Australian patent by the end of January with an expiration date of 14 March 2037. Similarly, the company is expecting Canadian patents to be granted by mid-January 2023, with an expiration date of 14 March 2037, for the first application described above, and by 15 November 2037 for the second application.

Image: © 2022 Kalkine Media®

Additionally, Dr Kilian Kelly stated that these patents further supported the company’s proprietary method of MSC production. It enables the effective production of therapeutic MSCs at scale with stable quality and avoids the need of multiple donors. The company is looking forward to the continued development of its patent estate while advancing its clinical programs in several therapeutic areas of high unmet medical need.

Recently, the DSMB has recommended Cynata to continue its Diabetic Foot Ulcer (DFU) clinical trial as planned.

Stock information

At the time of writing this article (17 October, 11:47 AM, AEST), the share price of CYP was AU$0.330.